Physiologically Based Pharmacokinetic Models in the Prediction of Oral Drug Exposure Over the Entire Pediatric Age Range—Sotalol as a Model Drug by Feras Khalil & Stephanie Läer
Research Article
Theme: Challenges and Opportunities in Pediatric Drug Development
Guest Editors: Bernd Meibohm, Jeffrey S. Barrett, and Gregory Knipp
Physiologically Based Pharmacokinetic Models in the Prediction of Oral Drug
Exposure Over the Entire Pediatric Age Range—Sotalol as a Model Drug
Feras Khalil1 and Stephanie Läer2,3
Received 31 July 2013; accepted 3 December 2013; published online 8 January 2014
Abstract. In recent years, the increased interest in pediatric research has enforced the role of
physiologically based pharmacokinetic (PBPK) models in pediatric drug development. However, an
existing lack of published examples contributes to some uncertainties about the reliability of their
predictions of oral drug exposure. Developing and validating pediatric PBPK models for oral drug
application shall enrich our knowledge about their limitations and lead to a better use of the generated
data. This study was conducted to investigate how whole-body PBPK models describe the oral
pharmacokinetics of sotalol over the entire pediatric age. Two leading software tools for whole-body
PBPK modeling: Simcyp® (Simcyp Ltd, Shefﬁeld, UK) and PK-SIM® (Bayer Technology Services
GmbH, Leverkusen, Germany), were used. Each PBPK model was ﬁrst validated in adults before scaling
to children. Model input parameters were collected from the literature and clinical data for 80 children
were used to compare predicted and observed values. The results obtained by both models were
comparable and gave an adequate description of sotalol pharmacokinetics in adults and in almost all
pediatric age groups. Only in neonates, the mean ratio(Obs/Pred) for any PK parameter exceeded a twofold
error range, 2.56 (95% conﬁdence interval (CI), 2.10–3.49) and 2.15 (95% CI, 1.77–2.99) for area under
the plasma concentration-time curve from the ﬁrst to the last concentration point and maximal
concentration (Cmax) using SIMCYP® and 2.37 (95% CI, 1.76–3.25) for time to reach Cmax using PK-
SIM®. The two PBPK models evaluated in this study reﬂected properly the age-related pharmacokinetic
changes and predicted adequately the oral sotalol exposure in children of different ages, except in
neonates.
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INTRODUCTION
Physiologically based pharmacokinetic (PBPK) models
can deliver valuable information during various stages of drug
development and research (1–4). Their ability to incorporate
information about maturation, growth, and age dependency
of anatomical and physiological processes facilitates their use
to extrapolate drug pharmacokinetics from adults to children
and to explore age-related changes (5,6). In recent years, the
implementation of PBPK models in pediatric drug develop-
ment has become more attractive (7–11), encouraged by an
increased awareness of/and interest in pediatric research,
especially after the new regulations on medicinal products for
pediatric use in both the USA and the European Union (12,13).
Despite the marked potential of PBPK models, uncer-
tainties still exist in the pediatric community about the accuracy
of their predictions especially after oral drug administration in
pediatric patients of different ages (11). The lack of sufﬁcient
published pediatric PBPK models evaluated adequately for the
prediction of oral drug absorption and disposition is one main
reason. For the intravenous (IV) application, six pediatric
whole-body PBPK models evaluated with a total of 10 different
drugs have already been reported (4,14–18). By contrast, there
is only, to date of writing, two publications with reported
pediatric PBPK model predictions evaluated for 6 drugs after
oral drug application (4,19), with only one of them evaluated
with neonatal experimental data for the modeled drug (19). In
addition, there are other reported pediatric PBPK models that
were, however, either not evaluated with experimental data
(20,21), or focused only on one aspect of the drug pharmaco-
kinetics with no full concentration-time proﬁles or information
about predicted drug absorption or exposure, e.g., to predict
only the clearance of the drugs (22,23). Given all of these facts,
more examples of evaluated pediatric PBPK models for oral
drugs are still in demand.
In recognition of this unmet need, a PBPK model drug
with an already available large-scale clinical pharmacokinetic
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data set that covers all pediatric age groups is preferable.
Sotalol, an antiarrhythmic drug used in the treatment of
supraventricular tachycardia, orally given with >90% bioavail-
ability and almost completely renally eliminated, has been very
well studied in both adults and children and fulﬁlls this
requirement (24–37). The rich pediatric data of sotalol facilitate
a good assessment of the model predictability from adolescents
down to neonates, and provide individual full concentration-
time proﬁles with information on drug absorption. Conversely,
the rich adult data after both IV and oral administration will
enable the validation of themodel ﬁrst in adults before scaling it
to children, thus forming a solid basis for age extrapolation.
Finally, because commercial PBPKmodeling packages are often
used nowadays by researchers as a basis for their models, and
because no single source for the integrated data does exist, the
choice to use two commonly used modeling software tools for
model development has been undertaken to minimize bias by
software and to examine to what extent the use of different
modeling software can inﬂuence the obtained results.
This study was made to investigate how whole-body
PBPK models, developed using two dedicated PBPK model-
ing tools, describe the oral pharmacokinetics of sotalol from
adults to neonates. A secondary goal was to observe any
differences in the performance of these two models across the
pediatric age range.
MATERIALS AND METHODS
PBPK Modeling Software and Model Parameterization
To develop a whole-body PBPK model of sotalol, two
specialized modeling software tools were used separately:
software 1 was Simcyp® simulator v.12.1 (Simcyp Ltd,
Shefﬁeld, UK) for adults and pediatrics (38), and software 2
was PK-SIM® v.4.2.2 (Bayer Technology Services GmbH,
Leverkusen, Germany) with its integrated clearance scaling
module (39). In brief, these tools provide a general PBPK
model structure to describe drug absorption and disposition
in the body and incorporate a large data set of anatomical and
physiological parameters with their age dependencies, as
permitted by the current scientiﬁc knowledge. The detailed
structure and methodology of these PBPK models are already
published elsewhere (40,41).
However, to complete the model parameterization, the
required physicochemical properties of sotalol, along with other
drug-dependent parameters, were collected from a comprehen-
sive literature search. Both models used the same values for
molecular weight, lipophilicity (octanol–water partition coefﬁ-
cient (logP) value), acid dissociation constant (pKa), fraction
unbound (fu), and clearance (CL), as listed in Table I
(24,25,31,43,47,60), which summarizes the ﬁnal model input
parameters. The total clearance of sotalol was set to be
0.1125 L h−1 kg−1 assigned completely as a renal clearance,
which is consistent, in its value and the route of elimination, with
the literature (24,25,31). The partition coefﬁcients in the tissues
were calculated with both software using Rodgers and
Rowland’s distribution model (42). The input values assigned
to the blood-to-plasma concentration (B/P) ratio differed
between software 1 and 2 (1.02 vs. 0.86), as these values gave
the best visual ﬁt during the IV model development (see
Modeling Strategy and Simulation Conditions); however, the
models predicted similar Vss values, 1.3 and 1.22 L/kg,
respectively, in an average adult male individual weighing
70 kg, which are in good agreement with the reported
literature values (24,31,43,44). Drug absorption was predicted
by the advanced dissolution, absorption, and metabolism
(ADAM) model in Simcyp (45), and by a built-in absorption
model in PK-SIM (46), with various input measures offered by
the two software to account for the drug intestinal permeability.
Sotalol is known to be a biopharmaceutics classiﬁcation system
(BCS) Class I drug with high solubility and high permeability
proﬁle; however, sotalol in vitro measured apparent
permeability coefﬁcient (Papp) is very low and does not
correlate with the high values of absorbed dose fraction
(>90%) obtained from pharmacokinetic studies in humans
(47,48). Therefore, the value of the intestinal permeability
measure for each model was adjusted separately in order to
give the same absorbed fraction and a bioavailability of 90% in
adult. Finally, the default mean values used in both models for
gastric emptying time (GET) and small intestinal transit time
(SITT) were 0.5 and 4 h, respectively.
Pharmacokinetic/Clinical Data
In Adults. MEDLINE database was screened for phar-
macokinetic studies of sotalol in healthy adults with known
age, gender, height or weight, clear dosing information, and
available plasma concentration-time proﬁles. As a result, a
total of 27 data sets originating from 11 clinical trials
published by 8 different scientiﬁc groups (between 1976 and
2010) in 5 countries (26–36) were used in model development
and evaluation (Table II) (26–36). Each experimental data set
represents a mean observed concentration-time proﬁle in an
average of ﬁve to six healthy volunteers who received either
IV or oral doses of sotalol-HCl. These data were either
provided by the author (35,36) or scanned from the publica-
tions’ ﬁgures (26–34).
In Children. Eighty pediatric patients of different age
groups with known age, gender, height, weight, dosing
information, and measured plasma proﬁles were used. The
majority of these data are already published (37). These
patients, ranging from age 11 days to 17.7 years (average,
3.51 years, including 13 premature infants) received various
doses of sotalol (1.0–9.9 mg kg−1 day−1) for the treatment of
supraventricular tachycardia. The demographics of these
children are presented in Fig. 1. This pediatric data set was
classiﬁed using a system similar to the WHO classiﬁcation,
however, using six different age groups: (a) neonates, 0–
28 days (n=14); (b) infants, 1–11 months (n=33); (c) toddlers,
12–23 months (n=6); (d) Preschool-aged, 2–5 years (n=10);
(e) school-aged, 6–11 years (n=13); and (f) adolescents, 12–
18 years (n=4). This classiﬁcation was used for presenting
results in children.
Modeling Strategy and Simulation Conditions
The adopted modeling strategy is shown in Fig. 2. An
adult model was ﬁrst developed for the IV application, as this
allows for the kinetics of drug disposition to be simulated in
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the absence of the complexities of the absorption process.
Thus, the best set of input parameters, the suitable distribu-
tion model, and the most appropriate clearance that collec-
tively gave the best visual description of the observed data
used at this stage, were assigned. For the oral application,
parameters values from the previous step were kept plus the
values of additional parameters that control and inﬂuence
drug absorption, such as intestinal permeability, GET, and
SITT. In the previously mentioned steps (i.e., model build-
ing), only one ﬁfth (n=5) of the collected adult data set was
used, whereas the remaining data (n=22) were used later for
a subsequent model veriﬁcation. The adult model was slightly
reﬁned (logP and CL inputs) before the end model evalua-
tion. The ﬁnal adult model was then scaled down to children,
taking into consideration the age dependencies of anatomical
and physiological processes/parameters and the ontogeny of
clearance pathways, which are already integrated into the
modeling software, to predict pediatric sotalol exposure (see
also, Clearance Scaling).
The comparison of model results with observed data was
based on simulations of virtual populations, where the main
results of these simulations are concentration-time proﬁles. In
adults, each virtual population consisted of 100 virtual
subjects having the same age range, race, gender composition,
and dosing as their respective real population. The resulting
mean plasma concentrations were then compared with the
mean observed concentrations for model evaluation.
Population simulations performed with a higher number of
virtual subjects (n=1,000) did not produce any signiﬁcant
difference from the previous ones (using 100 replicates), and
did not inﬂuence any differences seen between the results of
both models. In children, a similar approach was used by
performing a population simulation of 100 virtual children
each with the same age, race, gender, and dosing information
Table I. Input Parameters for Sotalol PBPK Models Using Both Modeling Software
Parameter Software 1a value Software 2b value Reference value Reference
Molecular weight (g/mol) 272.36 272.36 272.36 PubChem
LogP(o/w) 0.37 0.37 0.2, 0.37 PubChem, (47)
Ionization constant pKa1=8.28 pKa1=8.28 pKa1=8.28 (60)
pKa2=9.72 pKa2=9.72 pKa2=9.72
fu 1 1 1 (24,25,43)
Blood/plasma ratio 1.02 0.86 1.07 (60)
CLIV, total 7.875 L/h 0.1125 L h
−1 kg−1 0.09–3.2 L h−1 kg−1 (31,43,44)
Fraction of renal clearance 100% 100% 90–100% (24,25)
Permeability measure (cm/s)c 2.01×10−4c 12.6×10−6c – –
LogP octanol–water partition coefﬁcient, fu fraction unbound, CLIV, total total intravenous clearance, pKa acid dissociation constant, pKa1 for
acidic function, pKa2 for basic function
a Simcyp®
b PK-SIM®
cHuman jejunum permeability (Peff, man) as permeability measure in software 1; in vitro intestinal permeability (Papp) as permeability
measure in software 2. Both measures were manually adjusted to give the same value of fraction absorbed (fa) and a bioavailability of 90%
Table II. Population Characteristics and Dosing Information of the Pharmacokinetic Studies Used in the Development and Validation of the
Sotalol Adult PBPK Model
Applied dose
No. of data setsa Ethnicity Females (%) Age range (years) References(mg) (mg/kg)
Intravenous sotalol 20 – 1 Caucasian 50 24–53 (26)
35b 0.5 2 Caucasian 50 18–38 (27)
70b 1 1 Asian 0 22–43 (28)
75 – 1 Caucasian 60 19–45 (29)
105b 1.5 4 Caucasian/Asian 18 18–43 (27,28,30)
140b 2 2 Caucasian 0 21–32 (30,31)
210b 3 2 Caucasian 50 18–38 (27)
Oral sotalol 40 – 1 Asian 0 22–45 (32)
50 – 1 Asian 0 22–43 (28)
80 – 2 Caucasian 60 19–45 (29,32)
100 – 2 Caucasian/Asian 0 22–43 (31)
160 – 5 Caucasian/Asian 16 22–56 (26,32,33,35,36)
200 – 1 Asian 0 22–43 (28)
300 – 1 Asian 0 22–43 (28)
320 – 1 Caucasian 10 28–56 (34)
aEach data set represents a mean observed concentration time proﬁle of an average of ﬁve to six healthy adult volunteers
bTotal dose in milligrams was calculated from the reported milligrams per kilogram dose using a reference adult weight value of 70 kg
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of a real child; however, the resulting median plasma
concentrations were used along with the individual observed
concentrations in the model evaluation. For all previous
simulations, variability ranges for CL, GET, and SITT were
assigned to account for the interindividual variability. These
values were either set by the software, as in software 1—CL:
mean value±30% CV; GET: mean value±38% CV; SITT:
Weibull distribution around the mean value with α=2.92 and
β=4.04; or were assigned manually based on a comprehensive
literature search as in software 2: lognormal distribution with
geometric standard deviation of 1.3 for CL, GET: uniform
distribution of 0.2–1.9 h in adults (49,50) and 0.2–2.1 h in
children (51–54), and SITT: normal distribution with a mean
value of 4±1 h in both (49,55).
Clearance Scaling
The modeling tools used here employ a physiology-based
scaling of adult clearance to children. In short, data sets of
experimentally obtained clearances of various substances, for
which elimination were primarily due to one process, were
previously collected and used to develop and validate
ontogeny patterns accounting for the maturation of various
elimination pathways over the pediatric age, including renal
elimination (22,23). These ontogeny proﬁles are incorporated
in the used modeling tools, and employed along age-speciﬁc
differences in bodyweight, eliminating organs weight and
blood ﬂow, and protein binding in order to scale adult
clearance value (model input) to children of different age.
This physiology-based scaling of clearance was shown to
accurately predict clearance in children from birth to
adolescence (22,23) and was found superior to that of
allometric scaling.
Evaluation of Model Performance
Visual predictive checks for superimposed predicted and
observed plasma concentration-time proﬁles, and goodness of
ﬁt plots were used for the graphical analysis of model results.
Moreover, the area under the plasma concentration-time
curve from the ﬁrst to the last concentration point (AUClast),
the maximal concentration (Cmax) with the time to reach it
(tmax), and the elimination-rate constant (ke) were calculated
via a noncompartmental analysis for each observed proﬁle
Fig. 1. The height and/or weight (dots) of each of the 80 children (boys, n=54 (right); girls, n=26 (left)); the observed
population originally exposed to sotalol. In addition, lines show pediatric age- and gender-speciﬁc percentiles (3rd, 10th,
50th, 90th, and 97th), which represent the normal values of a German representative population (61). Insets show the
demographics of the segment from birth to the end of the ﬁrst year to highlight the values of newborns and infants
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and its corresponding predicted value from each model.
AUClast was calculated via the trapezoidal method, ke as the
slope of the last three concentrations on a natural logarithmic
scale (in children: only for plasma proﬁles measured over at
least 10 h, n=66/80), whereas Cmax and tmax were manually
determined as in deﬁnition. An observed/predicted ratio
(ratioObs/Pred) was then calculated and the ﬁnal results were
reported as mean ratios(Obs/Pred) with a nonparametric 95%
conﬁdence interval (CI) derived from 10,000 bootstrap
repetitions. A twofold error range from the observed values
for model predictions was set as a reference. Such a range is
commonly reported by other researchers and is considered
appropriate for a predictive model (14,16,19). Finally, per-
centage error (PE) and absolute percentage error (APE)
were calculated for every concentration point in each drug
administration in adults and children as follows:
PE ¼ CPRED−COBSð Þ
COBS
 100% ð1Þ
APE ¼ CPRED−COBSj j
COBS
 100% ð2Þ
To numerically describe the model accuracy and preci-
sion, the median percentage error (MDPE) and median
absolute percentage error (MDAPE; with a nonparametric
95% CI derived from 10,000 bootstrap repetitions) were
reported, respectively, as suggested in Sheiner and Beal (56).
All of the previously mentioned calculations were done using
MATLAB 2012a (57).
RESULTS
Simulation Results in Adults
A comparison between mean simulated and mean ob-
served plasma concentration-time proﬁles for four representa-
tive data sets in adults is shown in Fig. 3 (26,28,32,35). In general,
the two presented models were able to accurately describe
sotalol exposure after IVand oral application over a total dose
range of 20 to 320 mg (0.2–4.5 mg/kg BW) and for both
Caucasians and Asians. The resulted AUClast ratios(Obs/Pred)
were within 0.8–1.25 in 100% (27/27) and in 92.6% (25/27) of
the observed values using software 1 and 2, respectively, and
with all predictions contained within the range 0.5–2.
Moreover, the adult model did not show any difference in
the predictability of sotalol exposure after IV or oral
application. The mean AUClast ratio(Obs/Pred) for all simulat-
ed data sets using software 1 was 0.997 and 0.94 after IV and
oral applications, respectively. These results were similar
using software 2 as the mean AUClast ratio(Obs/Pred) was 0.94
for the IV and 0.987 for the oral application. Figure 4 shows
the predicted vs. observed plots for plasma concentrations,
AUClast, Cmax, tmax, and ke.
Fig. 2. Schematic workﬂow of the developed PBPK models
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The calculated numerical metrics indicate good accuracy
by both models. Software 1 showed no bias with a MDPE
value (95th bootstrap CI) of 1.36% (−1.37 to 3.17), in
comparison to a slight bias of 3.17% (1.63–5.23) in the model
Fig. 3. Comparison of predicted (lines; mean, 5–95th percentiles, min/max) and mean observed (dots; ±SD) concentrations
of IV and oral sotalol after various dosing in both Caucasians (a, b) and Asians (c, d). Simulations were performed using
software 1 (SIMCYP®, left column, filled circles) and 2 (PK-SIM®, right column, empty circles). Observed data are obtained
from Refs. (26,28,32,35)
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Fig. 4. Goodness of ﬁt plots for simulations of adult data by both sotalol PBPK models. a Predicted vs. observed
concentrations plot, b–e predicted vs. observed AUClast, Cmax, tmax, and ke plots. Results are obtained by using software 1
(SIMCYP®, left column, filled circles) and software 2 (PK-SIM®, right column, empty circles). Line, line of unity; dashed
lines, twofold error range;MDPE median percentage error (95% CI),MDAPE median absolute percentage error (95% CI)
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generated using software 2, which is, however, minimal and has
no clinical relevancy. Finally, both models showed similar
precision (deviation less than 10%) as the MDAPE for all
predicted concentration points was 9.91% (8.79–10.96) and
9.76% (8.56–10.85) using software 1 and 2, respectively (Fig. 4).
Simulation Results in Pediatrics
Using both modeling software applications, the extrapo-
lated model corresponding to the pediatric population
showed acceptable correlated predictions to in vivo data in
adolescents down to infants, with a pronounced deviation in
neonates. A comparison between median simulated and
observed plasma proﬁles for six representative pediatric
patients of each age group is shown in Fig. 5 (37).
Only in neonates were the both models unable to
predict a mean ratio(Obs/Pred) of all four PK parameters
within the predeﬁned twofold error range (Fig. 6). Using
software 1, the mean ratios(Obs/Pred) were 2.56 (95% CI, 2.10–
3.49) and 2.15 (95% CI, 1.77–2.99) for AUClast and Cmax,
respectively. Using software 2, the mean ratio(Obs/Pred) of tmax
was 2.37 (95% CI, 1.76–3.25). The elimination-rate constant
was reasonably predicted by both models as indicated by a
mean ratio of 0.55 and 0.81 for the software 1 and the 2
model, respectively.
In all remaining age groups, the mean ratios(Obs/Pred)
for the chosen PK parameters were within a twofold error
range irrespective of the model used, which indicates a
good predictive performance and a proper description of
the age-related pharmacokinetic changes of sotalol. The
95% CI of the mean ratios for all PK parameters was
contained within the range of 0.5 to 2, except for tmax in
some age groups (Fig. 6).
Furthermore, both models showed a general tendency
to underestimate sotalol concentrations as seen with the
negative MDPE values in almost all age groups and the
lower accuracy and precision values when compared with
the adult model (see Fig. 7). The least accuracy in
predicting individual concentration points was seen in
neonates for software 1 (MDPE=−54.8%) and in infants
for software 2 (MDPE=29.2%), whereas for both models
the highest accuracy was seen in adolescents. On the
other hand, the pediatric model imprecision was less than
40% in all groups except in neonates using software 1
(MDAPE=54.8%) and in infants using software 2
(MDAPE=43.6%), with the best model precision seen in
adolescents using both software (MDAPE=15.7%, 15.6%
for software 1 and 2, respectively).
DISCUSSION
Whole-body PBPK models for sotalol, an orally given
drug, were developed using two specialized modeling soft-
ware tools. The presented models were able to successfully
describe sotalol pharmacokinetics in adults and over a wide
range of the pediatric age, except in neonates. The results
obtained by both models were comparable and showed
differences only in children under 1 year of age.
Following the methodological approach, PBPK
models of sotalol were ﬁrst developed and evaluated in
adults. Both models were able to accurately and reliably
predict sotalol exposure after a wide range of IV and oral
dosing (Figs. 3 and 4), which indicate that they adequately
captured the major processes driving sotalol pharmacoki-
netics. The initial development and validation of the
model in adults present a modeling strategy that forms a
solid basis for age extrapolation to increase the accuracy
of the pediatric model predictions. Such a strategy is
common in the development of pediatric models and is
already used by other researchers (16,17,19).
In adolescents down to infants, the pediatric models
seemed to properly reﬂect the age-related changes in sotalol
pharmacokinetics, as indicated by the adequate description of
the experimental plasma proﬁles, which was further supported
by the numerical metrics and a good prediction of AUCtlast,
Cmax, tmax, and ke indicated by a mean ratio(Obs/Pred) within a
twofold error range (Figs. 5, 6, and 7). It was only for tmax,
where the calculated 95%CI exceeded the twofold error range
in some age groups; however, this could be explained, except
for infants, by the relatively low number of included children.
Comparing our results with the other available pediatric model
for the oral application, Parrot et al. reported in a model for the
oral oseltamivir and its metabolite a predicted AUC in infants
that was within a twofold range of the observed value (19),
which resembles our ﬁnding using both software for the same
age group.
In neonates, no model was able to predict a mean
ratio(Obs/Pred) for all reported PK parameters (AUClast, Cmax,
tmax, and ke) within the predeﬁned twofold error range, and,
therefore, the results were judged as inadequate (Fig. 6). The
noticed deviation was seen for parameters reﬂecting the
extent and rate of drug absorption (AUClast, Cmax, or tmax)
rather than drug disposition (ke). In the previously mentioned
model by Parrot et al., a difference of more than twofold upon
AUC prediction of oseltamivir and its metabolite in neonates
was obtained, which is similar to our ﬁndings (19). A mean
ratio(Obs/Pred) higher than two for any PK parameter—as in
our results—implies that the model predicts a value that is, on
average, less than half of the experimentally observed one.
Nevertheless, the clinical relevancy of such results should be
eventually judged taking additionally into consideration the
intended use of the generated data, and the allowable error
by the drug (e.g., low for drugs with narrow therapeutic
window). For example, this deviation seen in neonates would
be of more clinical relevancy if the model is intended to be
used to make dose recommendations than to suggest
sampling times. In the former case, any recommendations in
neonates based on such low predicted AUC, in comparison to
the observed, could lead to recommending higher therapeutic
doses than necessary with potential toxicity (e.g., torsades de
pointes with sotalol) as a clinical consequence.
Both of the presented models performed similarly in
adults and in almost all pediatric age groups with the only
discrepancy seen in children less than 1 year of age. First,
whereas the software 1 model tended to under-predict
plasma concentrations in all age groups, including infants
and neonates (negative MDPE), the software 2 model
under-predicted plasma concentrations only in children
over 1 year of age. Finally, in neonates, the software 1
model was unable to accurately predict the extent of drug
absorption as indicated by a mean ratio(Obs/Pred) exceeding
2 for AUClast and Cmax, whereas the software 2 model did
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not adequately predict the rate of drug absorption (tmax)
in the same age group.
We suggest that the inaccuracy of the predictions seen in
neonates is attributed to the absorption rather than elimination or
distribution process. This is because the major factors that
inﬂuence sotalol disposition (e.g., maturation of the renal
function, the age-related differences in body composition, tissue
volumes, and blood ﬂows) are well characterized over the entire
Fig. 5. Comparison of predicted (lines; median, 5–95th percentiles) vs. individual observed (symbols) plasma concentrations
in six representative pediatric patients from adolescents (a) to neonates (f), after various dosing of oral sotalol. Predictions
were made using software 1 (Simcyp®, left, filled circles) and 2 (PK-SIM®, right, empty circles). Observed data are taken
from Refs. (37)
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pediatric age range and are successfully implemented in the used
modeling tools, which should make the scaled information (e.g.,
clearance) a good estimate. In this exercise, both models were
able to acceptably predict the elimination-rate constant in all
pediatric age groups (Fig. 6). However, the marginally accepted
low mean ratio(Obs/Pred) for ke in neonates, using software 1,
indicate relatively high predicted values that are most probably
attributed to high predicted clearance in this age group. As a
result, the potential inﬂuence of any inaccuracy in clearance
scaling on the obtained results in neonates should not be
completely excluded.
By contrast, the absorption process is more complex and
involves many factors apart from the pharmaceutical formu-
lation of the drug. The ﬁrst set of them are anatomical and
physiological such as gastrointestinal organs volume and
blood ﬂow, radius, length and effective surface area, pH,
GET, SITT, metabolizing enzymes, transporters, and ﬂuid
secretion. Inﬂuenced, in part, by difﬁculties in obtaining age-
speciﬁc information in the literature, an age-speciﬁc value is
not incorporated for all of these factors in the pediatric
absorption models integrated within the used modeling tools,
which makes them an aspect to improve (Table III). For
instance, the ADAM model used by software 1 to predict the
oral drug absorption is under further improvement to ﬁll such
gaps with age-speciﬁc values, e.g., for metabolizing enzymes,
transporter, pH proﬁle, and volume of secreted ﬂuids. As
sotalol is not metabolized, not actively transported through-
out the gastrointestinal tract, and highly soluble, an age-
related change in the pH proﬁle could be the sole possible
factor from this list to inﬂuence its extent of absorption.
The second set of parameters is drug dependent such as
solubility, pKa, volume/size of the molecule and its intestinal
permeability. Concerning the latter, Yang et al. suggested
paracellular transport to play a major role in sotalol
permeability (47). Dahan et al. stated that, in adults, sotalol
shows a unique permeability pattern as a combination of a
basic moiety, with pKa and logP values within a critical range,
and that sotalol permeability in the distal small intestine is
high and compensates for its low permeability in the proximal
segments (58), which explains the low in vitro measured
jejunal permeability of sotalol, the BCS class I drug. In
recognition of this information, the predictions of software 1
model in neonates would have been improved, if a higher
permeability of sotalol is assumed and incorporated into the
model, as it has already been reported that paracellular
transport is higher in neonates than in adults because of wider
tight junctions (59). Conversely, the ﬁndings of Dahan et al.
highlight the role of higher pH values in sotalol absorp-
tion, and points out a rationale to incorporate different
values of permeability throughout the intestinal segments,
which could improve software 2 model predictions.
Running simulation scenarios by the presented PBPK
pediatric models would clarify, reject, or conﬁrm these
assumptions and would help in detecting the most
inﬂuential factor on sotalol absorption.
Limitations
The two presented models were not completely identical in
their input parameters (Table I); however, the different input
values of B/P ratio and intestinal permeability measures resulted
eventually in similar Vss and bioavailability values and, thus, are
not likely to be responsible for any major ﬁnding. Second,
although the work presented here would contribute to a better
understanding, and thus to a more correct use of the PBPK
model-generated data in the pediatric population, sotalol is a
Fig. 6. Comparison between the observed and predicted values of a the area under the plasma concentration-time curve (AUClast), b maximum
concentration (Cmax), c time of the maximum concentration (tmax), and d the elimination-rate constant (ke) in adults oral studies and in
children. Results are presented as mean ratios in each age group (symbols—circles for software 1 results, squares for software 2 results) with a
95% conﬁdence interval (horizontal lines)
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drug with a relatively simple pharmacokinetic proﬁle, i.e.,
renally excreted, not metabolized, unbound to plasma
proteins, and is not known to be actively transported
(24,25); therefore, the used software tools may not
necessarily do as well with predictions for drugs with
more complex pharmacokinetics. In addition to that,
sotalol is a BCS class I drug with a high solubility and a
high permeability proﬁle, which means that this exercise
will give no information on the accuracy of the drug
absorption in the lower intestinal segments and its age
Fig. 7. Median predicted vs. individual observed concentration plots for 80 pediatric patients stratiﬁed in 6 pediatric age
groups from a adolescents to f neonates. Results are obtained by using software 1 (SIMCYP®, left column, filled circles) and
2 (PK-SIM®, right column, empty circles). Line, line of unity; dashed lines, twofold error range; MDPE median percentage
error (95% CI), MDAPE median absolute percentage error (95% CI)
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dependence. As a result, further examples with drugs that
possess different pharmacokinetic proﬁles (e.g., hepatic
elimination with ﬁrst-pass effect or with involvement of
transporters) and physicochemical properties (e.g., of
different BCS grouping) are still needed.
Implications and Generalizations
This work was not designed to investigate new insights
on the pharmacokinetics of sotalol, as they are already
extensively studied in both adults and children (24–37).
However, the current work is planned to support a future
pediatric clinical trial, which will aim to develop a safe IV
dosing regimen as a substitution of oral sotalol in children
with supraventricular tachycardia by providing the necessary
sampling times for an optimal pharmacokinetic analysis.
Additionally, such validated models could play a role in
supporting clinical decision making in individual patients, for
example, with reduced renal function.
The obtained results in infants through adolescents
indicate a good model predictability and, thus, substantiate
the use of PBPK models to generate data a priori for this age
group, saving time, effort, and resources. This could be
probably generalized to other orally given drugs that share
a similar pharmacokinetic behavior as sotalol. Alternatively,
the lower model predictability of sotalol pharmacokinetics
seen in neonates indicates the need for a more cautious use of
model-generated data in this age group, acknowledging that
the ﬁnal judgment depends on the purpose of the model and
the properties of the modeled drug.
CONCLUSIONS
In summary, the PBPK models presented in this article
have shown good predictability of observed data in adults and
in almost all pediatric age groups, except in neonates where a
lower predictive performance was seen, which indicates a
more cautious use of model-generated data in this age group.
These results encourage the use of PBPK models, especially
when adult data are available, to predict oral drug exposure
in a wide range of pediatric age, which can aid in supporting
pediatric clinical trials, and, potentially, the clinical decision
making for individual children.
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